Author Correction: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study.

Ciresi, Alessandro; Vigneri, Enrica; Radellini, Stefano; Pantò, Felicia; Giordano, Carla

Ciresi, Alessandro; Vigneri, Enrica; Radellini, Stefano; Pantò, Felicia; Giordano, Carla.

Afiliação

Ciresi A; Section of Endocrinology, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy.
Vigneri E; Section of Endocrinology, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy.
Radellini S; Section of Endocrinology, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy.
Pantò F; Section of Endocrinology, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy.
Giordano C; Section of Endocrinology, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy. carla.giordano@unipa.it.

Diabetes Ther ; 9(3): 1413, 2018 06.

Article em En | MEDLINE | ID: mdl-29637460

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália